Abstract:ABCB1 is a promising therapeutic target for overcoming multidrug resistance (MDR). In this work, we reported the structure-based design of triazolo[1,5-a]pyrimidines as new ABCB1 modulators, of which WS-691 significantly increased sensitization of ABCB1-overexpressed SW620/Ad300 cells to paclitaxel (PTX) (IC50 = 22.02 nM). Mechanistic studies indicated that WS-691 significantly increased the intracellular concentration of PTX and [3H]-PTX while decreasing the efflux of [3H]-PTX in SW620/Ad300 cells by inhibiting the efflux function of ABCB1. The cellular thermal shift assay suggested that WS-691 could stabilize ABCB1 by directly binding to ABCB1. WS-691 could stimulate the activity of ABCB1 ATPase but had almost no inhibitory activity against CYP3A4. Importantly, WS-691 increased the sensitivity of SW620/Ad300 cells to PTX in vivo without observed toxicity. Collectively, WS-691 is a highly potent and orally active ABCB1 modulator capable of overcoming MDR. The triazolo[1,5-a]pyrimidine may be a promising scaffold for developing more potent ABCB1 modulators.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01741?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01741</a>.Cell survival rates under the nontoxic concentration of compounds toward selected cancer cells NMR, HRMS, and HPLC spectra of compounds 5–55 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01741/suppl_file/jm0c01741_si_001.pdf">PDF</a>)Coordinates of modeled structures in PDB format: WS-36 in complex with ABCB1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Q9H">4Q9H</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01741/suppl_file/jm0c01741_si_002.pdb">PDB</a>)Coordinates of modeled structures in PDB format: WS-691 in complex with ABCB1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4Q9H">4Q9H</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01741/suppl_file/jm0c01741_si_003.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01741/suppl_file/jm0c01741_si_004.csv">CSV</a>)This article has not yet been cited by other publications.

Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach

Virtual Screening with a Structure-Based Pharmacophore Model to Identify Small-Molecule Inhibitors of CARM1

Identification and Empiric Evaluation of New Inhibitors of the Multidrug Transporter P-Glycoprotein (ABCB1)

Pyrimidine: A promising scaffold for optimization to develop the inhibitors of ABC transporters

Development of Natural-Product-Inspired ABCB1 Inhibitors Through Regioselective Tryptophan C3-Benzylation

In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents

Exploration of 1,2,3-Triazole-pyrimidine Hybrids As Potent Reversal Agents Against ABCB1-mediated Multidrug Resistance

Cell-Based Screen Identifies a Highly Potent and Orally Available ABCB1 Modulator for Treatment of Multidrug Resistance

The Tetrahydroisoquinoline Scaffold in ABC Transporter Inhibitors that Act as Multidrug Resistance (MDR) Reversers

New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold

Synthesis and biological evaluation of thiophenylbenzofuran derivatives as potential P-glycoprotein inhibitors

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as potent reversal agents against ABCB1-mediated multidrug resistance

Structure-Based Discovery of ABCG2 Inhibitors: A Homology Protein-Based Pharmacophore Modeling and Molecular Docking Approach

Structure-Based Design, Synthesis, and Biological Evaluation of New Triazolo[1,5- a ]Pyrimidine Derivatives as Highly Potent and Orally Active ABCB1 Modulators

Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitors

2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations

Discovery of the Triazolo[1,5- a ]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance

Synthesis and evaluation of novel tetrahydroisoquinoline-benzo[ h ]chromen-4-one conjugates as dual ABCB1/CYP1B1 inhibitors for overcoming MDR in cancer

Consensus screening for a challenging target: the quest for P-glycoprotein inhibitors

Indole Derivatives as New Structural Class of Potent and Antiproliferative Inhibitors of Monocarboxylate Transporter 1 (MCT1; SLC16A1)

Evaluation of Novel Benzo-annelated 1,4-dihydropyridines as MDR Modulators in Cancer Cells